Liminatus Pharma raises $1.86M via warrant exercise inducement, issues new warrants for 20.7M shares

Liminatus Pharma, Inc.

Gross proceeds of ~$1.86M from exercise of 10.344M existing warrants at reduced exercise price of $0.18 per share.
Issued new unregistered warrants to purchase up to 20.688M common shares at $0.18, exercisable only after stockholder approval.
New warrants expire five years from stockholder approval date; resale registration to be filed within 20 days.
Maxim Group LLC acted as financial advisor, receiving 8% cash fee on gross proceeds.
Net proceeds from the exercise will be used for working capital and general corporate purposes.

item 1.01 item 3.02 item 3.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Liminatus Pharma, Inc. entered into Inducement Letter Agreement with a holder of its existing common stock warrants valued at $1,861,920.00 (effective 2026-06-03).

Action: entry
Agreement: equity purchase
Counterparty: a holder of its existing common stock warrants
Value: $1,861,920.00
Effective: 2026-06-03

Exact text from the filing

On June 3, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a warrant exercise inducement offer letter (the “Inducement Letter Agreement”) with a holder (the “Holder”) of its existing common stock warrants

View on SEC.gov

306 material agreements filed in the last 30 days. Browse all material agreements →

Liminatus Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-070173

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.